Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis

Alison Boyle*, Fiona Marra, Erica Peters, Shouren Datta, Trina Ritchie, Matthew Priest, Mathis Heydtmann, Stephen T. Barclay

*Corresponding author for this work

Research output: Contribution to journalArticle

76 Downloads (Pure)

Fingerprint Dive into the research topics of 'Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis'. Together they form a unique fingerprint.

Medicine & Life Sciences